Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

Strumberg, Dirk; Richly, Heike; A. Hilger, Ralf; Schleucher, N.; Korfee, Sönke; Tewes, Mitra; Faghih, Markus; Brendel, E.; Voliotis, D.; G. Haase, Claus; Schwartz, Brian; Awada, Ahmad; Voigtmann, R.; E. Scheulen, M.; Seeber, S.

doi:10.1200/jco.2005.06.124

Public

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

Published in Journal of Clinical Oncology • Dec 22, 2004

Authors:

Dirk Strumberg

Heike Richly

Ralf A. Hilger

Abstract

PURPOSE: BAY 43-9006 is a novel dual-action Raf kinase and vascular endothelial growth factor receptor inhibitor that inhibits tumor cell proliferation and angiogenesis. This study established the safety and pharmacokinetics of BAY 43-9006 in 69 patients with advanced refractory solid tumors. PATIEN...

Subject

Medicine

Pharmacokinetics

Toxicity

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!